ESPE Data Show BMI Reductions in Pediatric HO, Reinforcing Setmelanotide's Profile

What happened

Rhythm Pharmaceuticals presented new data at the European Society for Paediatric Endocrinology meeting, including real-world results from 30 pediatric patients with acquired hypothalamic obesity in France treated with setmelanotide for up to 18 months. The real-world data showed reductions in BMI, aligning with the favorable Phase 3 TRANSCEND results that underpin the pending regulatory submissions. Additional Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices, further supporting the drug's potential benefit in this indication. While these data are encouraging, they come from a small observational cohort and do not fundamentally change the investment case, which hinges on regulatory approval and successful commercial launch. The stock has already rerated sharply and trades at a valuation that embeds a smooth HO expansion, leaving limited room for execution missteps; this news is unlikely to alter the near-term trajectory.

Implication

Investors should view these presentations as incremental positive evidence for setmelanotide in hypothalamic obesity, but not as a catalyst that materially de-risks the approval or launch. The real-world data from 30 patients in France are encouraging but small and observational, and the Phase 3 cardiometabolic analyses are post-hoc supportive, so the core investment thesis still depends on the FDA decision and early commercial traction. With the stock trading around $105 and a market cap of ~$7 billion, the market is already pricing in a successful HO expansion and continued strong growth in the base franchise, leaving little margin for error. We continue to recommend waiting for either a pullback toward the $80 attractive entry level or clear evidence that HO launch is driving revenue acceleration with disciplined spending before adding to positions. Key monitoring points remain first-quarter HO launch metrics, payer coverage, expense growth relative to revenue, and cash runway, as these will determine whether the current premium is justified.

Thesis delta

The investment thesis remains unchanged at WAIT. This news adds supportive real-world and cardiometabolic evidence for setmelanotide in acquired HO, but it does not address the key risks of valuation stretch, launch execution, or financial discipline. The stock's premium still relies on flawless HO approval and launch, and these data, while positive, do not alter our conviction or price targets.